2024
Vitamin D’s Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study
Worhunsky P, Mignosa M, Gallezot J, Pittman B, Nabulsi N, Stryjewski A, Jalilian-Khave L, Trinko R, DiLeone R, Carson R, Malison R, Potenza M, Angarita G. Vitamin D’s Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study. Biological Psychiatry 2024, 97: 651-658. PMID: 39395473, PMCID: PMC11839384, DOI: 10.1016/j.biopsych.2024.09.028.Peer-Reviewed Original ResearchVentral striatumEffects of medicationDorsal caudateDopamine releaseDorsal putamenDopaminergic tonePlacebo-controlled within-subject studyIncreased amphetamine-induced dopamine releaseAmphetamine-induced dopamine releaseAmphetamine-stimulated dopamine releaseSubstantia nigraDysregulated dopamine functionPositron emission tomography studiesTreatment of ADHDEmission tomography studiesWithin-subject studyPost-amphetamineD2/3 receptorsDopamine functionTransdiagnostic relevanceVitamin DPhasic releaseGlobus pallidusStriatumTyrosine hydroxylase
2019
Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans
Ranganathan M, De Aquino JP, Cortes-Briones JA, Radhakrishnan R, Pittman B, Bhakta S, D’Souza D. Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2019, 236: 3209-3219. PMID: 31187152, DOI: 10.1007/s00213-019-05273-5.Peer-Reviewed Original ResearchConceptsCOMT rs4680 polymorphismMemory deficitsCOMT genotypeVal/Val individualsRs4680 polymorphismSubjective effectsTest dayCatechol-O-methyl transferase (COMT) enzymePsychotomimetic effectsCognitive effectsCognitive dataCannabinoid-dopamine interactionsAcute responseHuman brainIntravenous THCPlacebo-controlled studyRole of dopaminergicCatechol-O-methyl transferaseDopaminergic signalingAcute pharmacological inhibitionDeficitsCannabinoid effectsDopaminergic toneHealthy subjectsDrug development efforts
2017
The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [11C]FLB457 PET Study
Sandiego CM, Matuskey D, Lavery M, McGovern E, Huang Y, Nabulsi N, Ropchan J, Picciotto MR, Morris ED, McKee SA, Cosgrove KP. The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [11C]FLB457 PET Study. Neuropsychopharmacology 2017, 43: 1052-1058. PMID: 28944773, PMCID: PMC5854798, DOI: 10.1038/npp.2017.223.Peer-Reviewed Original ResearchConceptsTobacco smokersGuanfacine treatmentPositron emission tomographyTobacco smokingDA releaseDopaminergic toneDopamine releaseAmphetamine-induced DA releaseTobacco smoking cessationCortical dopamine releaseExtrastriatal brain regionsAlpha2-adrenergic agonistExtrastriatal dopamine releaseEffect of treatmentBaseline BPNDSmoking cessationReceptor radiotracerAdrenergic agonistsPET scansAnimal modelsBrain regionsEmission tomographyPET studiesDopamine signalingSmokers
2009
Novel Pharmacological Approaches to Drug Abuse Treatment
Edens E, Massa A, Petrakis I. Novel Pharmacological Approaches to Drug Abuse Treatment. Current Topics In Behavioral Neurosciences 2009, 3: 343-386. PMID: 21161760, DOI: 10.1007/7854_2009_29.Peer-Reviewed Original ResearchConceptsNovel pharmacological approachesPharmacological approachesAddiction treatmentDrug abuse treatmentDrugs of abuseWithdrawal discomfortDopaminergic tonePharmacologic researchRewarding effectsNeural pathwaysAbuse treatmentNeurobiological underpinningsTreatmentNicotineDrugsVaried treatmentsAdditional substancesComorbiditiesMedicationsOpiates
1994
Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment
Youngren K, Moghaddam B, Bunney B, Roth R. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neuroscience Letters 1994, 165: 41-44. PMID: 8015734, DOI: 10.1016/0304-3940(94)90704-8.Peer-Reviewed Original ResearchConceptsMedial prefrontal cortexChronic treatmentNucleus accumbensPrefrontal cortexChronic clozapine treatmentBasal dopamine releaseExtracellular dopamine levelsChronic clozapineClozapine treatmentIntracerebral microdialysisAcute doseDopaminergic toneDopamine levelsDopamine releaseExtracellular dopamineRat striatumDopamine overflowClozapineBrain regionsPreferential activationStriatumAccumbensCortexTreatmentMicrodialysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply